All In Biotech

NDA 219132 · Intrabio

Aqneursa

Levacetylleucine · Oral

NovelPriority reviewOrphan

CDER novel approval, Sep 24, 2024: To treat Niemann-Pick disease type C

Last checked: Nov 20, 2026Latest source record: Sep 18, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2024

Sep 24, 2024

Approved uses

2

Original approval plus efficacy supplements

Registered trials

1

1 Phase 3, 0 recruiting

FAERS reports

251

63 serious, 14 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Nov 13, 2026.

AQNEURSA is indicated for the treatment of: • neurological manifestations of Niemann-Pick disease type C (NPC) in adults and pediatric patients weighing ≥15 kg. ( 1.1 ) • ataxia in adults and pediatric patients with ataxia-telangiectasia (A-T) weighing ≥15 kg. ( 1.2 ) 1.1 Niemann-Pick Disease Type C AQNEURSA ® is indicated for the treatment of neurological manifestations of Niemann-Pick disease type C (NPC) in adults and pediatric patients weighing ≥15 kg. 1.2 Ataxia-Telangiectasia AQNEURSA is indicated for the treatment of ataxia in adults and pediatric patients with ataxia-telangiectasia (A-T) weighing ≥15 kg.

Mechanism: The distinct molecular target for levacetylleucine in the treatment of NPC or A-T is unknown.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Sep 18, 2026 Supplement 2 · Efficacy · priority review OrphanLabelLetter
  • Sep 24, 2024 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLabelLetterReview
1 products under this application
  • AQNEURSA · LEVACETYLLEUCINE 1GM/PACKET · FOR SUSPENSION, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Levacetylleucine" as an intervention, any sponsor and status, largest first.

All 1 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use140
  • fall11
  • product use in unapproved indication11
  • seizure11
  • vomiting9
  • dysphagia8
  • pneumonia8
  • gait disturbance7
  • pneumonia aspiration7
  • decreased appetite6
  • diarrhoea6
  • product use issue6

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20201
20231
20247
2025151
202691

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 3 on PubMed

Sponsor: Intrabio

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.